53 results about "Connective tissue disease" patented technology

Novel methods for treating or reducing the likelihood of acquiring symptoms or diseases due to the menopause, in postmenopausal women, particularly osteoporosis, vaginal atrophy and dryness, hypogonadism, diminished libido, skin atrophy, connective tissue disease, urinary incontinence, breast, endometrial, ovarian and uterine cancers, hot flashes, loss of muscle mass, insulin resistance, fatigue, loss of energy, aging, physical symptoms of menopause, in susceptible warm-blooded animals including humans involving administration of a sex steroid precursor are disclosed. Said method comprising novel ways of administering and dosing dehydroepiandrosterone (DHEA) in order to take advantage of positive androgenic effects in the vaginal layers lamina propia and/or the layer muscularis, without undesirably causing systemic estrogenic effects in order to avoid the risk of breast and uterine cancer. Pharmaceutical compositions for delivery of active ingredient(s) useful to the invention are also disclosed.

This invention relates to one anti-extracting nuclear antigen spectrum array to ELISA test agent case for selecting for systematic lupus erythematosus, mixed connective tissue disease, Sjogren syndrome, systemic scleroderma, polymyositis and atrophic arthritis system self immune property antigen ENA spectrum micro array to enzyme immune agent case.

The present invention relates to a Chinese medicine composition, and especially a kind of Chinese medicine composition for treating lupus erythematosus, systemic scieroderm, dermatomyositis, panniculitis, behcets disease and connective tissue disease and its preparation process. The Chinese medicine composition is preferably prepared into dripping pill and soft capsule.

Methods of treating inflammatory skin diseases such as rosacea, atopic dermatitis, contact dermatitis, drug eruptions, psoriasis, seborrheic dermatitis, connective tissue diseases, autoimmune disorders, urticaria or hives, and inflammation associated with skin infections by topical or systemic administration of a nitroxide containing compound are provided.

The present invention provides effective and safe medicaments for the treatment of connective tissue diseases of the skin, particularly with respect to the treatment of cutaneous forms of Lupus Erythematous. The medicaments comprise as the therapeutically active ingredient a beta₂ adrenoceptor agonist. The invention furthermore relates to dermatological compositions without skin sensitization properties and which contain enantiomerically pure or enriched R-enantiomers of a beta₂ adrenoceptor agonist.

The invention provides a method for predicting and verifying the curative effect of glucocorticoid based on image omics, which comprises the following steps: S1, acquiring an original medical image ofa patient using glucocorticoid to treat connective tissue disease related interstitial pulmonary disease, and dividing the obtained original medical image into a training group and a verification group; s2, performing quantification processing on the original medical image to obtain image omics feature data; s3, establishing a prediction model of the image omics characteristics in the training group, and performing test verification in the verification group; and step S4, determining effective clinical characteristics and image omics characteristic tags adopting glucocorticoid, and performingverification in a verification group. According to the method, the curative effect of glucocorticoid is predicted and verified on the basis of imaging omics so as to identify patients sensitive to glucocorticoid treatment, and a specific reference basis is provided for doctors to diagnose and treat patients with connective tissue related interstitial pulmonary diseases, so that the patients are effectively treated, and the success rate of treatment is increased.

The invention discloses a preparation method of superparamagnetism conductive nano gamma-ferric oxide/ polyaniline-dexamethasone sodium phosphate, relating to the technical field of synthesis of superparamagnetism conductive nano gamma-ferric oxide/ polyaniline-dexamethasone sodium phosphate. The superparamagnetism conductive nano gamma-ferric oxide/ polyaniline-dexamethasone sodium phosphate is prepared by a doping method. The product of the invention can better suspend in water, still has favorable electrochemical activity and electric conduction magnetoconductivity within the pH range of human body environment, and can directionally reach diseased tissues under the regulation and control of an external magnetic field without damaging normal clasmatocyte. The targeted medicine is hopefully applied to treating acute leukemia, malignant lymphoma, connective tissue diseases, rheumatoid arthritis and the like. In addition, the method of the invention is simple, convenient, economical and favourable for industrial production and application.

The invention discloses a kit for detecting an anti-moesin antibody. The kit comprises a solid-phase carrier and a moesin antigenic protein, wherein the moesin antigenic protein is a full-length human moesin. The kit can be applied to a method for early prediction and severity evaluation of connective tissue disease (CTD)-related lung involvement and evaluation is performed by mainly sampling a biological sample of a subject and detecting the quantity of the anti-moesin antibodies in the biological sample. The moesin is prepared by proteomics technology and gene recombination technology and an enzyme-linked immunosorbent assay (ELISA) detection kit for detecting the anti-moesin antibody is provided. The detectable rate of the kit for the CTD-related lung involvement is up to 51.7 percent.

The invention provides compounds that inhibit MMPs; methods for treating or preventing cancer, angiogenesis, arthritis, connective tissue disease, cardiovascular disease, inflammation or autoimmune disease in a mammal; a method for inhibiting a matrix metalloproteinase in vivo or in vitro; and a method for imaging a tumor in vivo or in vitro.

An embodiment of the invention provides a composition having one or more active ingredients such as an aminosugar, more particularly, glucosamine, glucosamine salt, and mixtures thereof, and a glycosaminoglycan, more particularly, chondroitin, chondroitin salts, and mixtures thereof having a therapeutic use and is stable for at least 24 months. Additionally, the composition includes a diluent, glidant, and lubricant. The invention also provides a method of treating a connective tissue disease, injury, or condition comprising administering to a mammal any one of the compositions described herein. The composition can be in tablet or capsule form.

The present invention relates to a method of treating functional disability and/or pain associated with joints, tendons or connective tissue diseases, disorders or injuries comprising oral administration of a composition comprising heterologous platelet-rich plasma. The invention also relates to pharmaceutical compositions and nutritional compositions comprising heterologous platelet-rich plasma and uses thereof.

The invention discloses an antigen-immobilized matrix membrane, a kit comprising the same for detecting an antinuclear antibody spectrum related to autoimmune diseases and purpose thereof. The antigen-immobilized matrix membrane comprises but not only comprises following 22 mutually independent antigen detection lines including double-stranded DNA, histone, ribosome P0 protein, PCNA, SmD1, SmD3, SmB/B', snRNP-A, snRNP-C, snRNP68/70, SSA/Ro60, SSA/Ro52, SSB/La, Jo-1, PL-7, PL-12, PmScl, Scl-70, CENP-A, CENP-B, RA33 and PR3. When the kit containing the antigen-immobilized matrix membrane is usedfor detection, 22 kinds of autoimmune antibodies can be detected simultaneously; and thus diagnosis of eight kinds of common diffuse connective tissue diseases is assisted.

The invention discloses a connective tissue disease-associated early interstitial lung disease diagnostic kit, comprising a detection module for detecting human peripheral blood MMP7, IFN-gamma and IP-10. The commercial kit provided by the invention is sensitive, safe, reliable and easy to operate; the kit is capable of quantificationally measuring the level of specific protein cytokines and chemotactic factors in human serum, and is helpful for early diagnosis of the connective tissue disease-associated interstitial lung disease.

The present invention provides a bee needle attenuation and effect-increase oral liquid and a preparation method thereof. The bee needle attenuation and effect-increase oral liquid comprises a cortex mori and clematis chinensis water extract and honey according to a volume ratio of (0.5-1.5):1, wherein cortex mori and clematis chinensis are taken according to a mass ratio of (2-5):(3-6) and then are subjected to mixing and water boiling extraction to obtain the cortex mori and clematis chinensis water extract. According to the present invention, the bee needle attenuation and effect-increase oral liquid is matched with the bee needle therapy so as to effectively reduce adverse reactions of patients after the bee needle therapy, enhance the bee needle therapy effect, provide the new assisted therapy method for rheumatoid arthritis, ankylosing spondylitis, other connective tissue diseases and rheumatic diseases, substantially increase the bee needle therapy safety, and provide the new idea and the effective method for overcome of the biggest limiting factor of the promotion of the bee needle therapy.

The invention discloses a plant extract composite buccal tablet, comprising the following raw materials: L-leucine, resveratrol, quercetin, anthocyanin, fisetin, pterostilbene, nicotinic acid, folic acid, chromium, magnesium, Coenzyme Q10, curcumin, lipoic acid, green tea extract, and milk thistle extract. According to the invention, the purely natural plant substances such as green tea extract and milk thistle extract added to the buccal tablet have significant therapeutic effect on respiratory diseases, digestive diseases, circulatory diseases, urinary system diseases, endocrine diseases, metabolic diseases, lymphatic diseases, neurological system diseases, connective tissue disease, gynecological diseases, otolaryngology diseases, stomatological diseases, orthopedic diseases, dermatological diseases, oncological diseases and other chronic degenerative diseases. Meanwhile, the buccal tablet is low in cost and free of side effects, has the efficacy of clearing heat and detoxifying, moving qi and activating blood, nourishing and strengthening body, regulating qi and invigorating stomach, benefiting qi and tonifying kidney, tranquilizing and tonifying spleen, and also is capable ofenhancing physical fitness to improve the immunity of the body to diseases.

The invention relates to a pharmaceutical composition of dexamethasone sodium phosphate for injection and a preparation method of the pharmaceutical composition, and in particular relates to a freeze-dried powder injection pharmaceutical composition of dexamethasone sodium phosphate. The freeze-dried powder injection pharmaceutical composition comprises dexamethasone sodium phosphate and a freeze-dried excipient which is selected from one or more of mannitol, glycine, lactose and saccharose, wherein the weight ratio of dexamethasone sodium phosphate to mannitol is 1:(1-50). The freeze-dried powder injection pharmaceutical composition of dexamethasone sodium phosphate disclosed by the invention is applicable to treatment of irritability and autoimmunity-related diseases, is particularly used for connective tissue diseases, active rheumatism, rheumatoid arthritis, lupus erythematosus, severe bronchial asthma, severe dermatitis, ulcerative colitis, acute leukemia and the like, and also can be used for comprehensive treatment on serious infection and poisoning, and malignant lymphoma. The freeze-dried powder injection pharmaceutical composition of dexamethasone sodium phosphate disclosed by the invention has excellent pharmaceutical property as described in the specification.